Company
Mirxes Holding Company Limited
HKEX:2629
Develops and sells blood-based microRNA diagnostic tests for early cancer detection. Its lead product, GASTROClear, is a 12-biomarker blood panel for gastric cancer screening; it also markets LUNGClear for lung cancer and Fortitude infectious-disease assays. The longevity relevance is early detection rather than any ageing-biology intervention: catching cancer at a screenable, asymptomatic stage in high-risk adults. Qualifies for the variis universe on the headquarters limb (Singapore), not the exchange limb, as it is listed on HKEX rather than SGX or ASX.
At a glance
- Listing
- HKEX:2629
- Category
- Diagnostics
- Headquarters
- Singapore
- Market cap
- HK$3.66bn (approx US$470m) as at 31 March 2026 per stockanalysis.com, down from a HK$8.29bn debut valuation on 23 May 2025; no verified mid-2026 quote retrieved
Thesis
Why it is in this universe
- Category
- Diagnostics
- Market
- Singapore
- Recent inflection
- 9 October 2025: China's NMPA granted GASTROClear Class III IVD registration, making it the first non-invasive blood test approved for gastric cancer screening in China, cleared for high-risk adults aged 45 to 74 on the basis of a 9,472-subject prospective trial across seven Chinese academic centres (Mirxes media release).
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | HKEX |
| Ticker | HKEX:2629 |
| Secondary listing | None |
| Market cap | HK$3.66bn (approx US$470m) as at 31 March 2026 per stockanalysis.com, down from a HK$8.29bn debut valuation on 23 May 2025; no verified mid-2026 quote retrieved |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Singapore
- Website
- www.mirxes.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
9 October 2025: China's NMPA granted GASTROClear Class III IVD registration, making it the first non-invasive blood test approved for gastric cancer screening in China, cleared for high-risk adults aged 45 to 74 on the basis of a 9,472-subject prospective trial across seven Chinese academic centres (Mirxes media release).
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
Every entity profile on variis is sourced. Not investment advice.